Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8472507 | 0.78 | P2RX4 (0.37) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL30040459 | 0.76 | P2RX4 (0.41) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL1723366 | 0.74 | P2RX4 (0.35) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL32679965 | 0.69 | CYP4Z1 (0.36) | P2RX4P2RX1P2RX3 | |
| SCHEMBL3628666 | 0.69 | MAOB (0.33) | P2RX4 | |
| SCHEMBL3262059 | 0.69 | MAOB (0.33) | P2RX4 | |
| SCHEMBL1198914 | 0.69 | P2RX4 (0.37) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL29434173 | 0.69 | P2RX4 (0.37) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL23043877 | 0.68 | CYP4Z1 (0.37) | P2RX4LMNAP2RX1P2RX3 | |
| SCHEMBL9420578 | 0.68 | TGM2 (0.37) | P2RX4LMNATSHRMAPK1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| US-4420308-A | Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | claimed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3273995-B1 | COMBINED USE OF ALGINATE OLIGOMERS AND THE CFTR MODULATOR LUMACAFTOR IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-02-04 | — | — | US | disclosed |
| EP-3768323-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-01-27 | — | — | EP | disclosed |
| CN-111867634-A | Enhanced translocation of micro/nanoparticles across the mucus layer using alginate oligomers | 阿尔吉法玛公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10751363-B2 | Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction | ALGIPHARMA AS (NO) | 2020-08-25 | — | — | US | disclosed |
| WO-2019180047-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2019-09-26 | — | — | WO | disclosed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | disclosed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | disclosed |
| US-4420308-A | Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | MUC1, ALG1, ST3GAL3 | P2RX4 3775/4885CYP1A2 4837/4885TDP1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.